Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erythromycin treatment in diffuse panbronchiolitis

S Kudoh1

  • 1Nippon Medical School, Internal Medicine Dept., Tokyo, Japan.

Current Opinion in Pulmonary Medicine
|June 5, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.

Japanese journal of clinical oncology·2014
Same author

Familial interstitial pneumonia in an adolescent boy with surfactant protein C gene (Y104H) mutation.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2013
Same author

Historical changes in epidemiology of diffuse panbronchiolitis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2013
Same author

Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Low-dose long-term erythromycin improves prognosis for diffuse panbronchiolitis, a chronic airway disease. Its benefits stem from anti-inflammatory actions, offering new insights into treatment.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Diffuse panbronchiolitis is a chronic infectious airway disease prevalent in the Far East.
  • Prognosis has significantly improved due to low-dose, long-term erythromycin therapy.
  • Erythromycin's efficacy is linked to anti-inflammatory rather than anti-infective properties.

Purpose of the Study:

  • To explore the anti-inflammatory mechanisms of erythromycin in diffuse panbronchiolitis.
  • To investigate the effects of erythromycin on airway epithelial and inflammatory cells.
  • To enhance understanding of the pathophysiology and treatment of chronic infectious airway diseases.

Main Methods:

  • Review of recent investigations on erythromycin's cellular actions.
  • Analysis of treatment outcomes in diffuse panbronchiolitis patients.

Related Experiment Videos

  • Exploration of the anti-inflammatory effects of 14-membered-ring macrolides.

    • Main Results:

    • Erythromycin demonstrates significant anti-inflammatory effects beyond its antimicrobial activity.
    • The drug modulates the function of neutrophils, lymphocytes, and macrophages.
    • Low-dose, long-term erythromycin therapy is associated with improved patient outcomes.

    Conclusions:

    • Erythromycin's anti-inflammatory action is key to its therapeutic benefit in diffuse panbronchiolitis.
    • Understanding these cellular interactions provides new avenues for treating chronic airway diseases.
    • This research deepens the knowledge of diffuse panbronchiolitis pathophysiology and management.